| Oct 13 |
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
|
| Oct 12 |
Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals
|
| Oct 4 |
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
|
| Sep 26 |
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
|
| Sep 24 |
Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc
|
| Sep 4 |
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
|
| Sep 4 |
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
|
| Sep 3 |
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
|
| Sep 3 |
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
|
| Sep 2 |
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
|
